TiGenix Announces Positive 52-week Phase III Results Of Cx601; Shares Up

(RTTNews) - Shares of TiGenix NV (TIG) were gaining around 3 percent in the early morning trading in Belgium after the biopharmaceutical company focused on allogeneic, or donor-derived, stem cells to develop novel therapies, announced Thursday positive 52-week results from its ADMIRE-CD Phase III clinical trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease.

The ADMIRE-CD Phase III trial demonstrated the long-term efficacy and safety of Cx601 for treatment-refractory complex perianal fistulas, the company noted.

The company said the results have been selected for an oral presentation at the World Congress of Gastroenterology at the American Congress of Gastroenterology 2017 Annual Scientific Meeting (WCOG/ACG) taking place from October 13-18, 2017 in Orlando, Florida, USA.

Mary Carmen Diez, Vice President, Medical Affairs and Commercialisation at TiGenix, said, "These data have been used to further support our marketing authorisation application for TiGenix, for which we anticipate a CHMP opinion in 2017. In parallel, we continue to progress our global pivotal Phase III trial for a future filing in the US."

In Belgium, TiGenix shares were trading at 1.11 euros, up 2.69 percent.